摘要
目的探讨埃索美拉唑联合喹诺酮类抗生素对幽门螺杆菌(Helicobacter pylori,Hp)阳性胃溃疡患者炎症因子的影响。方法选取2015年3月-2016年6月宁波市第二医院收治的Hp阳性胃溃疡患者90例,随机均分为2组,对照组予以奥美拉唑为主的三联方案,研究组予以埃索美拉唑+喹诺酮类抗生素为主的三联方案,2组均治疗14d,采血测定2组患者治疗前后胃功能、炎症因子及实验相关指标,同时对比临床疗效。结果与治疗前比较,2组治疗后腹痛、腹胀、嗳气、反酸等症状积分降低;GAS、PGⅠ、PGⅡ含量降低;CRP、IL-1、IL-6、TNF-α含量降低;TGF-β1含量降低,α-抵抗素含量升高(P〈0.05)。与对照组比较,研究组治疗后腹痛、腹胀、嗳气、反酸等症状积分较低;GAS、PGⅠ、PGⅡ含量较低;CRP、IL-1、IL-6、TNF-α含量较低;TGF-β1含量较低,α-防御素含量较高(P〈0.05);研究组转阴率91.11%高于对照组71.11%(P〈0.05),研究组治疗总有效率91.11%高于对照组73.33%(P〈0.05)。结论埃索美拉唑联合喹诺酮类抗生素治疗Hp阳性胃溃疡疗效显著,能降低炎症因子,改善胃功能。
Objective To investigate the effect of esomeprazole combined with quinolones in the treatment of Hp positive gastric ulcer in patients in serum inflammatory factors. Methods 90 cases of Hp positive gastric ulcer were selected and randomly divided into two groups,the control group received omeprazole based triple therapy,the experiment group received esomeprazole plus quinolone based triple therapy,two groups were treated for 14 days. Gastric function,inflammatory factors and related indexes were detected by blood and the clinical effect were compared after the treatment. Results Compared with before treatment,scores of abdominal pain,abdominal distension,belching,acid reflux symptom decreased in two groups after treatment,levels of GAS,PG I and PG II decreased,levels of CRP,IL-1,IL-6 decreased,levels of TNF-β1 decreased,and the levels of α-resistin increased( P〈0. 05). Compared with the control group after the treatment,scores of abdominal pain,abdominal distension,belching,acid reflux symptom in the experiment group were lower,levels of GAS,PG I and PG II were lower,levels of CRP,IL-1,IL-6 were lower,levels of TNF-β1 were lower,and levels of α-resistin were higher( P〈0. 05). The negative rate in the experiment group 91. 11% was higher than the control group 71. 11%( P〈0. 05),and the effective rate in the experiment group 91. 11% was higher than the control group 73. 33%( P〈0. 05). Conclusion Esomeprazole combined with quinolones in the treatment of Hp positive gastric ulcer was effective,and it reduce inflammation,improve gastric function.
出处
《中国生化药物杂志》
CAS
2016年第11期94-97,共4页
Chinese Journal of Biochemical Pharmaceutics